166 related articles for article (PubMed ID: 37759316)
21. Increased frequency of TIGIT
Brauneck F; Haag F; Woost R; Wildner N; Tolosa E; Rissiek A; Vohwinkel G; Wellbrock J; Bokemeyer C; Schulze Zur Wiesch J; Ackermann C; Fiedler W
Oncoimmunology; 2021 Jun; 10(1):1930391. PubMed ID: 34211801
[TBL] [Abstract][Full Text] [Related]
22. PD-1 Expression on Circulating CD8
Saito H; Shimizu S; Kono Y; Murakami Y; Shishido Y; Miyatani K; Matsunaga T; Fukumoto Y; Ashida K; Fujiwara Y
Anticancer Res; 2019 Jan; 39(1):443-448. PubMed ID: 30591493
[TBL] [Abstract][Full Text] [Related]
23. [Intracellular cytokine expression characteristics of activated T lymphocytes in patients with acute myeloid leukemia].
Yang HZ; Wang J; Sun ZM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1161-4. PubMed ID: 18088457
[TBL] [Abstract][Full Text] [Related]
24. Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with
Tan J; Chen S; Lu Y; Yao D; Xu L; Zhang Y; Yang L; Chen J; Lai J; Yu Z; Zhu K; Li Y
Chin J Cancer Res; 2017 Oct; 29(5):463-470. PubMed ID: 29142466
[TBL] [Abstract][Full Text] [Related]
25. Expression of PD-L1 on regulatory B cells in patients with acute myeloid leukaemia and its effect on prognosis.
Shi Y; Liu Z; Wang H
J Cell Mol Med; 2022 Jun; 26(12):3506-3512. PubMed ID: 35610758
[TBL] [Abstract][Full Text] [Related]
26. Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis.
Park SH; You E; Park CJ; Cho YU; Jang S; Im HJ; Seo JJ; Park HS; Lee JH
Cytometry B Clin Cytom; 2020 Jul; 98(4):336-347. PubMed ID: 32268011
[TBL] [Abstract][Full Text] [Related]
27. Programmed Death Ligand-1 is Frequently Expressed in Primary Acute Myeloid Leukemia and B-Acute Lymphoblastic Leukemia.
Hamdan SO; Sughayer M; Khader M; Tbakhi A; Khudirat S; Hejazi A; AlRyalat S; Bustami N; Aladily TN
Clin Lab; 2022 Apr; 68(4):. PubMed ID: 35443604
[TBL] [Abstract][Full Text] [Related]
28. Aberrant expression of T cell activation markers and upregulation of Tregs in bone marrow and peripheral blood in acute myeloid leukemia patients.
Fang J; Zhang R; Lin X; Xu Y; Huang K; Saw PE
Hematology; 2023 Dec; 28(1):2219554. PubMed ID: 37288810
[TBL] [Abstract][Full Text] [Related]
29. Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia.
Zahran AM; Mohammed Saleh MF; Sayed MM; Rayan A; Ali AM; Hetta HF
Cancer Biomark; 2018; 22(3):587-595. PubMed ID: 29843224
[TBL] [Abstract][Full Text] [Related]
30. Higher frequency of the CTLA-4
Chen Y; Tan J; Huang S; Huang X; Huang J; Chen J; Yu Z; Lu Y; Weng J; Du X; Li Y; Zha X; Chen S
Asia Pac J Clin Oncol; 2020 Apr; 16(2):e12-e18. PubMed ID: 31612643
[TBL] [Abstract][Full Text] [Related]
31. Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells.
Ma J; Yan S; Zhao Y; Yan H; Zhang Q; Li X
Front Immunol; 2023; 14():1265255. PubMed ID: 37841254
[TBL] [Abstract][Full Text] [Related]
32. PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma.
Rataj F; Kraus FBT; Chaloupka M; Grassmann S; Heise C; Cadilha BL; Duewell P; Endres S; Kobold S
Front Immunol; 2018; 9():1955. PubMed ID: 30214445
[No Abstract] [Full Text] [Related]
33. CD8 + T cell-based molecular subtypes with heterogeneous immune landscapes and clinical significance in acute myeloid leukemia.
Zhong F; Yao F; Jiang J; Yu X; Liu J; Huang B; Wang X
Inflamm Res; 2024 Mar; 73(3):329-344. PubMed ID: 38195768
[TBL] [Abstract][Full Text] [Related]
34. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
[TBL] [Abstract][Full Text] [Related]
35. Triple combination targeting methyltransferase, BCL-2, and PD-1 facilitates antileukemia responses in acute myeloid leukemia.
Zeng Z; Maiti A; Herbrich S; Cai T; Cavazos A; Manzella T; Ma H; Hayes K; Matthews J; DiNardo CD; Daver NG; Konopleva MY
Cancer; 2023 Feb; 129(4):531-540. PubMed ID: 36477735
[TBL] [Abstract][Full Text] [Related]
36. T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.
Schnorfeil FM; Lichtenegger FS; Emmerig K; Schlueter M; Neitz JS; Draenert R; Hiddemann W; Subklewe M
J Hematol Oncol; 2015 Jul; 8():93. PubMed ID: 26219463
[TBL] [Abstract][Full Text] [Related]
37. Increased PD-1+Tim-3+ exhausted T cells in bone marrow may influence the clinical outcome of patients with AML.
Tan J; Yu Z; Huang J; Chen Y; Huang S; Yao D; Xu L; Lu Y; Chen S; Li Y
Biomark Res; 2020; 8():6. PubMed ID: 32082573
[TBL] [Abstract][Full Text] [Related]
38. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
39. PD1 expression on bone marrow T-cells in newly diagnosed Egyptian AML patients: Correlation with hematological parameters, aberrant antigens expression, and response to induction therapy.
Bassiouny N; El-Hoda N; Khalifa IM; Ibrahim S; Salem L; Annaka L
EJHaem; 2020 Jul; 1(1):51-57. PubMed ID: 35847700
[TBL] [Abstract][Full Text] [Related]
40. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
